Search

Your search keyword '"Almer, S"' showing total 472 results
Start Over Author "Almer, S"
472 results on '"Almer, S"'

5. A novel serum protein signature as biomarker for Inflammatory Bowel Disease : A diagnostic performance and prediction modelling study using data from two independent inception cohorts

Author

Bazov, Igor, Kruse, Robert, Bergemalm, Daniel, Eriksson, Carl, Hedin, C. R., Carlson, M., van Nieuwenhoven, Michiel, Keita, Å. V., Magnusson, M. K., Almer, S., Strid, H., Mathisen, C. Bache-Wiig, Bengtsson, M. B., Aabrekk, T. Bergene, Medhus, A. W., Detlie, T. E., Frigstad, S. O., Huppertz-Hauss, G., Opheim, R., Ricanek, P., Kristensen, V. A., Salihovic, Samira, D'Amato, M., Öhman, L., Söderholm, J. D., Lindqvist, C. M., Repsilber, Dirk, Høivik, M. L., Halfvarson, Jonas, Bazov, Igor, Kruse, Robert, Bergemalm, Daniel, Eriksson, Carl, Hedin, C. R., Carlson, M., van Nieuwenhoven, Michiel, Keita, Å. V., Magnusson, M. K., Almer, S., Strid, H., Mathisen, C. Bache-Wiig, Bengtsson, M. B., Aabrekk, T. Bergene, Medhus, A. W., Detlie, T. E., Frigstad, S. O., Huppertz-Hauss, G., Opheim, R., Ricanek, P., Kristensen, V. A., Salihovic, Samira, D'Amato, M., Öhman, L., Söderholm, J. D., Lindqvist, C. M., Repsilber, Dirk, Høivik, M. L., and Halfvarson, Jonas

Published
2023

8. Search Result Caching in Peer-to-Peer Information Retrieval Networks

Author

Tigelaar, Almer S., Hiemstra, Djoerd, Trieschnigg, Dolf, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Nierstrasz, Oscar, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Sudan, Madhu, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Vardi, Moshe Y., Series editor, Weikum, Gerhard, Series editor, Hanbury, Allan, editor, Rauber, Andreas, editor, and de Vries, Arjen P., editor

Published
2011
Full Text
View/download PDF

10. Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with Inflammatory Bowel Disease — An ECCO-EpiCom study

Author

Burisch, J., Weimers, P., Pedersen, N., Cukovic-Cavka, S., Vucelic, B., Kaimakliotis, I., Duricova, D., Bortlik, M., Shonová, O., Vind, I., Avnstrøm, S., Thorsgaard, N., Krabbe, S., Andersen, V., Dahlerup, J.F., Kjeldsen, J., Salupere, R., Olsen, J., Nielsen, K.R., Manninen, P., Collin, P., Katsanos, K.H., Tsianos, E.V., Ladefoged, K., Lakatos, L., Ragnarsson, G., Björnsson, E., Bailey, Y., O'Morain, C., Schwartz, D., Odes, S., Valpiani, D., Boni, M.C., Jonaitis, L., Kupcinskas, L., Turcan, S., Barros, L., Magro, F., Lazar, D., Goldis, A., Nikulina, I., Belousova, E., Fernandez, A., Sanroman, L., Almer, S., Zhulina, Y., Halfvarson, J., Arebi, N., Diggory, T., Sebastian, S., Lakatos, P.L., Langholz, E., and Munkholm, P.

Published
2014
Full Text
View/download PDF

11. Health care and patients' education in a European inflammatory bowel disease inception cohort: An ECCO-EpiCom study

Author

Burisch, J., Vegh, Z., Pedersen, N., Čuković-Čavka, S., Turk, N., Kaimakliotis, I., Duricova, D., Bortlik, M., Shonová, O., Thorsgaard, N., Krabbe, S., Andersen, V., Dahlerup, J.F., Kjeldsen, J., Salupere, R., Olsen, J., Nielsen, K.R., Manninen, P., Collin, P., Katsanos, K.H., Tsianos, E.V., Ladefoged, K., Ragnarsson, G., Björnsson, E., Bailey, Y., O'Morain, C., Schwartz, D., Odes, S., Politi, P., Santini, A., Kiudelis, G., Kupcinskas, L., Turcan, S., Magro, F., Barros, L., Lazar, D., Goldis, A., Nikulina, I., Belousova, E., Sanromán, L., Martinez-Ares, D., Almer, S., Zhulina, Y., Halfvarson, J., Arebi, N., Houston, Y., Sebastian, S., Langholz, E., Lakatos, P.L., and Munkholm, P.

Published
2014
Full Text
View/download PDF

12. Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe — An ECCO-EpiCom study

Author

Burisch, J., Pedersen, N., Cukovic-Cavka, S., Turk, N., Kaimakliotis, I., Duricova, D., Bortlik, M., Shonová, O., Vind, I., Avnstrøm, S., Thorsgaard, N., Krabbe, S., Andersen, V., Dahlerup, J.F., Kjeldsen, J., Salupere, R., Olsen, J., Nielsen, K.R., Manninen, P., Collin, P., Katsanos, K.H., Tsianos, E.V., Ladefoged, K., Lakatos, L., Ragnarsson, G., Björnsson, E., Bailey, Y., O'Morain, C., Schwartz, D., Odes, S., Giannotta, M., Girardin, G., Kiudelis, G., Kupcinskas, L., Turcan, S., Barros, L., Magro, F., Lazar, D., Goldis, A., Nikulina, I., Belousova, E., Martinez-Ares, D., Hernandez, V., Almer, S., Zhulina, Y., Halfvarson, J., Arebi, N., Tsai, H.H., Sebastian, S., Lakatos, P.L., Langholz, E., and Munkholm, P.

Published
2014
Full Text
View/download PDF

13. Development of a core descriptor set for Crohn's anal fistula

Author

Lee M. J., Williams K. M., Lamidi S., Coe P. O., Bordeianou L. G., Hart A. L., Hind D., Lindsay J. O., Lobo A. J., Myrelid P., Raine T., Sebastian S., Fearnhead N. S., Adams K., Almer S., Ananthakrishnan A., Bethune R. M., Block M., Brown S. R., Cirocco W. C., Cooney R., Davies J., Atici S. D., Dhar A., Din S., Drobne D., Espin-Basany E., Evans J. P., Fleshner P. R., Folkesson J., Fraser A., Graf W., Hahnloser D., Hager J., Hancock L., Hanzel J., Hargest R., Hedin C. R. H., Hill J., Ihle C., Jongen J., Kader R., Karmiris K., Katsanos K. H., Keller D. S., Kopylov U., Koutrabakis I. E., Lamb C. A., Landerholm K., Lee G. C., Litta F., Limdi J. K., Lopes E. W., Madoff R. D., Martin S. T., Martin-Perez B., Michalopoulos G., Millan M., Munch A., Nakov R., Noor N. M., Oresland T., Paquette I. M., Pellino G., Perra T., Porcu A., Roslani A. C., Samaan M. A., Sebepos-Rogers G. M., Segal J. P., de Silva S., Soderholm M., Spinelli A., Speight A., Steinhagen R. M., Stenstrom P., Tsimogiannis K. E., Varma M. G., Verma A. M., Verstockt B., Warden C., Yassin N., Zawadzki A., Carr P., Devlin B., Mannick S., Avery P., Gecse K. B., Goren I., Hellstrom P. M., Kotze P. G., McWhirter D., Naik A. S., Sammour T., Selinger C. P., Stein S. L., Torres J., Wexner S. D., Younge L. C., Lee, M. J., Williams, K. M., Lamidi, S., Coe, P. O., Bordeianou, L. G., Hart, A. L., Hind, D., Lindsay, J. O., Lobo, A. J., Myrelid, P., Raine, T., Sebastian, S., Fearnhead, N. S., Adams, K., Almer, S., Ananthakrishnan, A., Bethune, R. M., Block, M., Brown, S. R., Cirocco, W. C., Cooney, R., Davies, J., Atici, S. D., Dhar, A., Din, S., Drobne, D., Espin-Basany, E., Evans, J. P., Fleshner, P. R., Folkesson, J., Fraser, A., Graf, W., Hahnloser, D., Hager, J., Hancock, L., Hanzel, J., Hargest, R., Hedin, C. R. H., Hill, J., Ihle, C., Jongen, J., Kader, R., Karmiris, K., Katsanos, K. H., Keller, D. S., Kopylov, U., Koutrabakis, I. E., Lamb, C. A., Landerholm, K., Lee, G. C., Litta, F., Limdi, J. K., Lopes, E. W., Madoff, R. D., Martin, S. T., Martin-Perez, B., Michalopoulos, G., Millan, M., Munch, A., Nakov, R., Noor, N. M., Oresland, T., Paquette, I. M., Pellino, G., Perra, T., Porcu, A., Roslani, A. C., Samaan, M. A., Sebepos-Rogers, G. M., Segal, J. P., de Silva, S., Soderholm, M., Spinelli, A., Speight, A., Steinhagen, R. M., Stenstrom, P., Tsimogiannis, K. E., Varma, M. G., Verma, A. M., Verstockt, B., Warden, C., Yassin, N., Zawadzki, A., Carr, P., Devlin, B., Mannick, S., Avery, P., Gecse, K. B., Goren, I., Hellstrom, P. M., Kotze, P. G., Mcwhirter, D., Naik, A. S., Sammour, T., Selinger, C. P., Stein, S. L., Torres, J., Wexner, S. D., Younge, L. C., Gastroenterology and Hepatology, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
Crohn's disease, anal fistula, consensus, methodology, Gastroenterologi, Gastroenterology, consensu, Gastroenterology and Hepatology
Abstract

Aim: Crohn's anal fistula (CAF) is a complex condition, with no agreement on which patient characteristics should be routinely reported in studies. The aim of this study was to develop a core descriptor set of key patient characteristics for reporting in all CAF research.Method: Candidate descriptors were generated from published literature and stakeholder suggestions. Colorectal surgeons, gastroenterologists and specialist nurses in inflammatory bowel disease took part in three rounds of an international modified Delphi process using nine-point Likert scales to rank the importance of descriptors. Feedback was provided between rounds to allow refinement of the next ratings. Patterns in descriptor voting were assessed using principal component analysis (PCA). Resulting PCA groups were used to organize items in rounds two and three. Consensus descriptors were submitted to a patient panel for feedback. Items meeting predetermined thresholds were included in the final set and ratified at the consensus meeting.Results: One hundred and thirty three respondents from 22 countries completed round one, of whom 67.0% completed round three. Ninety seven descriptors were rated across three rounds in 11 PCA-based groups. Forty descriptors were shortlisted. The consensus meeting ratified a core descriptor set of 37 descriptors within six domains: fistula anatomy, current disease activity and phenotype, risk factors, medical interventions for CAF, surgical interventions for CAF, and patient symptoms and impact on quality of life.Conclusion: The core descriptor set proposed for all future CAF research reflects characteristics important to gastroenterologists and surgeons. This might aid transparent reporting in future studies.

Published
2022

15. Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis

Author

Hedin, C, Sado, G, Ndegwa, N, Lytvyak, E, Mason, A, Montano-Loza, A, Gerussi, A, Saffioti, F, Thorburn, D, Nilsson, E, Larsson, G, Moum, B, van Munster, K, Ponsioen, C, Levy, C, Nogueira, N, Bowlus, C, Gotlieb, N, Shibolet, O, Lynch, K, Chapman, R, Rupp, C, Vesterhus, M, Jorgensen, K, Rorsman, F, Schramm, C, Sabino, J, Vermeire, S, Zago, A, Cazzagon, N, Marschall, H, Ytting, H, Ben Belkacem, K, Chazouilleres, O, Almer, S, Bergquist, A, Hedin C. R. H., Sado G., Ndegwa N., Lytvyak E., Mason A., Montano-Loza A., Gerussi A., Saffioti F., Thorburn D., Nilsson E., Larsson G., Moum B. A., van Munster K. N., Ponsioen C. Y., Levy C., Nogueira N. F., Bowlus C. L., Gotlieb N., Shibolet O., Lynch K. D., Chapman R. W., Rupp C., Vesterhus M., Jorgensen K. K., Rorsman F., Schramm C., Sabino J., Vermeire S., Zago A., Cazzagon N., Marschall H. -U., Ytting H., Ben Belkacem K., Chazouilleres O., Almer S., Bergquist A., Hedin, C, Sado, G, Ndegwa, N, Lytvyak, E, Mason, A, Montano-Loza, A, Gerussi, A, Saffioti, F, Thorburn, D, Nilsson, E, Larsson, G, Moum, B, van Munster, K, Ponsioen, C, Levy, C, Nogueira, N, Bowlus, C, Gotlieb, N, Shibolet, O, Lynch, K, Chapman, R, Rupp, C, Vesterhus, M, Jorgensen, K, Rorsman, F, Schramm, C, Sabino, J, Vermeire, S, Zago, A, Cazzagon, N, Marschall, H, Ytting, H, Ben Belkacem, K, Chazouilleres, O, Almer, S, Bergquist, A, Hedin C. R. H., Sado G., Ndegwa N., Lytvyak E., Mason A., Montano-Loza A., Gerussi A., Saffioti F., Thorburn D., Nilsson E., Larsson G., Moum B. A., van Munster K. N., Ponsioen C. Y., Levy C., Nogueira N. F., Bowlus C. L., Gotlieb N., Shibolet O., Lynch K. D., Chapman R. W., Rupp C., Vesterhus M., Jorgensen K. K., Rorsman F., Schramm C., Sabino J., Vermeire S., Zago A., Cazzagon N., Marschall H. -U., Ytting H., Ben Belkacem K., Chazouilleres O., Almer S., and Bergquist A.

Abstract

Background & Aims: Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC and IBD, and their efficacy in treatment of IBD. Methods: We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical response, as determined by the treating clinician or measurements of fecal calprotectin. Remission was defined more stringently as endoscopic mucosal healing. We used linear regression analysis to identify factors associated significantly with level of ALP during anti-TNF therapy. Results: Anti-TNF treatment produced a response of IBD in 48% of patients and remission of IBD in 23%. There was no difference in PSC symptom frequency before or after drug exposure. The most common reasons for anti-TNF discontinuation were primary nonresponse of IBD (17%) and side effects (18%). At 3 months, infliximab-treated patients had a median reduction in serum level of ALP of 4% (interquartile range, reduction of 25% to increase of 19%) compared with a median 15% reduction in ALP in adalimumab-treated patients (interquartile range, reduction of 29% to reduction of 4%; P =.035). Factors associated with lower ALP were normal ALP at baseline (P <.01), treatment with adalimumab (P =.090), and treatment in Europe (P =.083). Conclusions: In a retrospective analysis of 141 patients with PSC and IBD, anti-TNF agents were moderately effective and were not associated with exacerbation of PSC symptoms or specific side effects. Prospective studies are needed to inv

Published
2020

19. East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort

Author

Burisch, J, Pedersen, N, Čuković-Čavka, S, Brinar, M, Kaimakliotis, I, Duricova, D, Shonová, O, Vind, I, Avnstrøm, S, Thorsgaard, N, Andersen, V, Krabbe, S, Dahlerup, J F, Salupere, R, Nielsen, K R, Olsen, J, Manninen, P, Collin, P, Tsianos, E V, Katsanos, K H, Ladefoged, K, Lakatos, L, Björnsson, E, Ragnarsson, G, Bailey, Y, Odes, S, Schwartz, D, Martinato, M, Lupinacci, G, Milla, M, De Padova, A, DʼIncà, R, Beltrami, M, Kupcinskas, L, Kiudelis, G, Turcan, S, Tighineanu, O, Mihu, I, Magro, F, Barros, L F, Goldis, A, Lazar, D, Belousova, E, Nikulina, I, Hernandez, V, Martinez-Ares, D, Almer, S, Zhulina, Y, Halfvarson, J, Arebi, N, Sebastian, S, Lakatos, P L, Langholz, E, and Munkholm, P

Published
2014
Full Text
View/download PDF

21. Real-world effectiveness of vedolizumab in ulcerative colitis : Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study

Author

Eriksson, Carl, Rundquist, Sara, Lykiardopoulos, V., Udumyan, Ruzan, Karlén, P., Grip, O., Söderman, C., Almer, S., Hertervig, E., Gunnarsson, J., Malmgren, C., Delin, J., Strid, H., Sjöberg, M., Öberg, D., Bergemalm, Daniel, Hjortswang, H., Halfvarson, Jonas, Eriksson, Carl, Rundquist, Sara, Lykiardopoulos, V., Udumyan, Ruzan, Karlén, P., Grip, O., Söderman, C., Almer, S., Hertervig, E., Gunnarsson, J., Malmgren, C., Delin, J., Strid, H., Sjöberg, M., Öberg, D., Bergemalm, Daniel, Hjortswang, H., and Halfvarson, Jonas

Published
2020
Full Text
View/download PDF

25. CARD4/NOD1 is not involved in inflammatory bowel disease. (Inflammatory Bowel Disease)

Author

Zouali, H., Lesage, S., Merlin, F., Cezard, J-P., Colombel, J-F., Belaiche, J., Almer, S., Tysk, C., O'Morain, C., Gassull, M., Christensen, S., Finkel, Y., Modigliani, R., Gower-Rousseau, C., Macry, J., Chamaillard, M., Thomas, G., and Hugot, J-P.

Subjects
Inflammatory bowel diseases -- Genetic aspects, Health
Abstract

Background and aims: Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are complex genetic disorders. CARD15/NOD2, a member of the Ced4 super-family which includes Apaf-1 and [...]

Published
2003

29. P714 Real-world effectiveness of vedolizumab in ulcerative colitis: Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study

Author

ERIKSSON, C, primary, Rundquist, S, additional, Lykiardopoulos, V, additional, Udumyan, R, additional, Karlén, P, additional, Grip, O, additional, Söderman, C, additional, Almer, S, additional, Hertervig, E, additional, Gunnarsson, J, additional, Malmgren, C, additional, Delin, J, additional, Strid, H, additional, Sjöberg, M, additional, Öberg, D, additional, Bergemalm, D, additional, Hjortswang, H, additional, and Halfvarson, J, additional

Published
2020
Full Text
View/download PDF

42. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis

Author

Weismueller, T, Strassburg, C, Trivedi, P, Hirschfield, G, Bergquist, A, Said, K, Imam, M, Lazaridis, K, Juran, B, Cheung, A, Lindor, K, Lenzen, H, Manns, M, Ponsioen, C, Beuers, U, Holm, K, Naess, S, Karlsen, T, Schrumpf, E, Boberg, K, Gotthardt, D, Rupp, C, Faerkkilae, M, Jokelainen, K, Marschall, H, Benito De Valle, M, Thorburn, D, Saffioti, F, Weersma, R, Fevery, J, Mueller, T, Chazouillãres, O, Schulze, K, Schramm, C, Almer, S, Pereira, S, Levy, C, Mason, A, Bowlus, C, Floreani, A, Halilbasic, E, Trauner, M, Yimam, K, Milkiewicz, P, Huynh, D, Pares, A, Manser, C, Dalekos, G, Eksteen, B, INVERNIZZI, PIETRO, Berg, C, Kirchner, G, Sarrazin, C, Zimmer, V, Fabris, L, Braun, F, Marzioni, M, Chapman, R, Hansen, B, Hansen, B., AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, Weismueller, T, Strassburg, C, Trivedi, P, Hirschfield, G, Bergquist, A, Said, K, Imam, M, Lazaridis, K, Juran, B, Cheung, A, Lindor, K, Lenzen, H, Manns, M, Ponsioen, C, Beuers, U, Holm, K, Naess, S, Karlsen, T, Schrumpf, E, Boberg, K, Gotthardt, D, Rupp, C, Faerkkilae, M, Jokelainen, K, Marschall, H, Benito De Valle, M, Thorburn, D, Saffioti, F, Weersma, R, Fevery, J, Mueller, T, Chazouillãres, O, Schulze, K, Schramm, C, Almer, S, Pereira, S, Levy, C, Mason, A, Bowlus, C, Floreani, A, Halilbasic, E, Trauner, M, Yimam, K, Milkiewicz, P, Huynh, D, Pares, A, Manser, C, Dalekos, G, Eksteen, B, Invernizzi, P, Berg, C, Kirchner, G, Sarrazin, C, Zimmer, V, Fabris, L, Braun, F, Marzioni, M, Chapman, R, Hansen, B, Clinicum, Department of Medicine, Gastroenterologian yksikkö, HUS Abdominal Center, Universitat de Barcelona, Gastroenterology & Hepatology, and Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI)

Subjects
Male, Risk Stratification, Time Factors, Cholangitis, POPULATION-BASED COHORT, Ulcerative, Kaplan-Meier Estimate, Gastroenterology, Inflammatory bowel disease, Sclerosing, 0302 clinical medicine, Crohn Disease, Retrospective Studie, MED/12 - GASTROENTEROLOGIA, Risk Factors, Autoimmune Liver Disease, Multivariate Analysi, Crohn's disease, Cholestasis, Incidence, Hazard ratio, Immune-Mediated Liver Disease, Adult, Age Distribution, Australia, Chi-Square Distribution, Cholangitis, Sclerosing, Colitis, Ulcerative, Disease Progression, Europe, Female, Humans, Liver Transplantation, Middle Aged, Multivariate Analysis, North America, Phenotype, Prognosis, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Sex Distribution, Young Adult, Colitis, Ulcerative colitis, Inflamació, CROHNS-DISEASE, 3. Good health, ULCERATIVE-COLITIS, Cholestasi, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Human, medicine.medical_specialty, Time Factor, Prognosi, Lower risk, Article, Primary sclerosing cholangitis, 03 medical and health sciences, Colitis ulcerosa, Internal medicine, medicine, GENOME-WIDE ASSOCIATION, PRIMARY BILIARY-CIRRHOSIS, Inflammation, Hepatology, business.industry, Proportional hazards model, Risk Factor, CLINICAL PRESENTATION, Retrospective cohort study, DOSE URSODEOXYCHOLIC ACID, NATURAL-HISTORY, medicine.disease, digestive system diseases, 3121 General medicine, internal medicine and other clinical medicine, RISK-FACTORS, Proportional Hazards Model, business, SINGLE-CENTER
Abstract

BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary disorder associated with inflammatory bowel disease (IBD). We aimed to estimate the risk of disease progression based on distinct clinical phenotypes in a large international cohort of patients with PSC. METHODS: We performed a retrospective outcome analysis of patients diagnosed with PSC from 1980 through 2010 at 37 centers in Europe, North America, and Australia. For each patient, we collected data on sex, clinician-reported age at and date of PSC and IBD diagnoses, phenotypes of IBD and PSC, and date and indication of IBD-related surgeries. The primary and secondary endpoints were liver transplantation or death (LTD) and hepatopancreatobiliary malignancy, respectively. Cox proportional hazards models were applied to determine the effects of individual covariates on rates of clinical events, with time-to-event analysis ascertained through Kaplan-Meier estimates. RESULTS: Of the 7121 patients in the cohort, 2616 met the primary endpoint (median time to event of 14.5 years) and 721 developed hepatopancreatobiliary malignancy. The most common malignancy was cholangiocarcinoma (n = 594); patients of advanced age at diagnosis had an increased incidence compared with younger patients (incidence rate: 1.2 per 100 patient-years for patients younger than 20 years old, 6.0 per 100 patient-years for patients 21-30 years old, 9.0 per 100 patient-years for patients 31-40 years old, 14.0 per 100 patient-years for patients 4150 years old, 15.2 per 100 patient-years for patients 51-60 years old, and 21.0 per 100 patient-years for patients older than 60 years). Of all patients with PSC studied, 65.5% were men, 89.8% had classical or large-duct disease, and 70.0% developed IBD at some point. Assessing the development of IBD as a time-dependent covariate, Crohn's disease and no IBD (both vs ulcerative colitis) were associated with a lower risk of LTD (unadjusted hazard ratio [HR], 0.62; P

Published
2017

46. Clinical effectiveness of golimumab : Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG

Author

Eriksson, Carl, Bergemalm, Daniel, Vigren, L., Nilsson, L., Visuri, Isabella, Hjortswang, H., Udumyan, Ruzan, Almer, S., Seddighzadeh, M., Hertervig, E., Karlen, P., Strid, H., Halfvarson, Jonas, Eriksson, Carl, Bergemalm, Daniel, Vigren, L., Nilsson, L., Visuri, Isabella, Hjortswang, H., Udumyan, Ruzan, Almer, S., Seddighzadeh, M., Hertervig, E., Karlen, P., Strid, H., and Halfvarson, Jonas

Abstract

Funding Agency:MSD

Published
2018

47. Golimumab är effektivt vid ulcerös kolit under svenska förhållanden. Interimsanalys av en svensk prospektiv multi-centerstudie, GO-SWIBREG

Author

Eriksson, C., Bergenmalm, D., Vigren, L., Nilsson, L., Visuri, I., Hjortswang, H., Udumyan, Ruzan, Almer, S., Seddighzadeh, M., Hertervig, E., Karlén, P., Stridh, H., The GO-SWIBREG, Study Group, Halfvarson, Jonas, Eriksson, C., Bergenmalm, D., Vigren, L., Nilsson, L., Visuri, I., Hjortswang, H., Udumyan, Ruzan, Almer, S., Seddighzadeh, M., Hertervig, E., Karlén, P., Stridh, H., The GO-SWIBREG, Study Group, and Halfvarson, Jonas

Abstract

Bakgrund: Randomiserade kontrollerade prövningar har visat effekt av golimumab vid ulcerös kolit men studiedeltagare och förhållanden i kliniska prövningar motsvarar inte alltid svensk klinisk vardag. Syftet med denna studie var att utvärdera säkerhet och effekt av behandling med golimumab vid ulcerös kolit under svenska förhållanden. Metod: Detta är en prospektiv kohortstudie med inklusion av patienter från svenska sjukhus. Patienter med måttlig till svår aktiv ulcerös kolit, definierad som endoskopiskt Mayo score ≥2 och som påbörjade golimumab fr.o.m. 1/6-2014 inkluderades efter att informerat samtycke inhämtats. Kliniska karakteristika, behandling, klinisk-, biokemisk- och endoskopisk aktivitet liksom skattning av livskvalité samlades in vid inklusion samt prospektivt med hjälp av ett elektroniskt studieformulär, integrerat i svenska kvalitetsregistret för IBD (SWIBREG). Primärt effektmått var klinisk effekt vid 3 samt 12 månader (definierat som minskat Mayo score med ≥3 poäng eller 30 % från inklusion), samt klinisk remission (definierad som Mayo score ≤ 2 utan några enskilda poäng >1). Kontinuerliga data presenteras som median och kvartilavstånd. För statistisk jämförelse mellan inklusion och uppföljning användes Wilcoxon-signed rank test. Data från induktionsbehandling samt 3-månadersuppföljning presenteras här. Resultat: 50 patienter inkluderades t.o.m. 15/9-2017. Vid studiestart var 24/50 (48 %) samtidigt behandlade med immunmodulerare, 16/50 (32 %) med perorala kortikosteroider samt 27/50 (54 %) med 5-ASA. Totalt hade 35/50 (70 %) tidigare fått behandling med minst en TNF-hämmare (tabell 1). Efter 12 veckor hade 37/50 (74 %), fortfarande behandling med golimumab. Av de patienter som fortsatte med golimumab till vecka 12 var 8 (22 %) i klinisk remission och 13 (35 %) uppvisade klinisk respons. Totalt Mayo score minskade i median från 7 (6-10) vid inklusion till 5 (1-8) vid 12 veckor (p<0.01). Fekalt calprotektin minskade från 710 (275-1850) µg/g till 3

Published
2018

48. Clinical effectiveness of vedolizumab : Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD)

Author

Eriksson, Carl, Rundquist, Sara, Lykiardopoulos, V., Karlen, P., Grip, O., Söderman, C., Almer, S., Hertervig, E., Gunnarsson, J., Malmgren, C., Delin, J., Strid, H., Sjöberg, M., Öberg, D., Bergemalm, Daniel, Udumyan, Ruzan, Hjortswang, H., Halfvarson, Jonas, Eriksson, Carl, Rundquist, Sara, Lykiardopoulos, V., Karlen, P., Grip, O., Söderman, C., Almer, S., Hertervig, E., Gunnarsson, J., Malmgren, C., Delin, J., Strid, H., Sjöberg, M., Öberg, D., Bergemalm, Daniel, Udumyan, Ruzan, Hjortswang, H., and Halfvarson, Jonas

Published
2018

49. Clinical effectiveness of vedolizumab : Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC)

Author

Eriksson, Carl, Rundquist, Sara, Lykiardopoulos, V., Karlen, P., Grip, O., Söderman, C., Almer, S., Hertervig, E., Gunnarsson, J., Malmgren, C., Delin, J., Strid, H., Sjöberg, M., Öberg, D., Bergemalm, Daniel, Udumyan, Ruzan, Hjortswang, H., Halfvarson, Jonas, Eriksson, Carl, Rundquist, Sara, Lykiardopoulos, V., Karlen, P., Grip, O., Söderman, C., Almer, S., Hertervig, E., Gunnarsson, J., Malmgren, C., Delin, J., Strid, H., Sjöberg, M., Öberg, D., Bergemalm, Daniel, Udumyan, Ruzan, Hjortswang, H., and Halfvarson, Jonas

Abstract

Funding Agency:Takeda

Published
2018

50. PERANCANGAN PROTOTIPE BIOREAKTOR UNTUK PENGOLAHAN LANJUT LIMBAH CAIR PABRIK KELAPA SAWIT (LCPKS) SECARA AEROBIK

Author

Teuku Husaini, Tri Afrianty, Irvan, Jhon Almer S. Pasaribu, and Bambang Trisakti

Subjects
Activated sludge, Materials science, Waste management, Constant velocity, Bioreactor, Paddle, Baffle, Aeration, Turbine, Activated sludge system
Abstract

LCPKS further processing is usually done by using activated sludge system is implemented in an open pond.This system requires a large enough dissolved oxygen so that if the system would lead to poor aeration then the HRT will be great. In addition to the spread of foul smell due to the system being used is open. This study aims to produce a prototype bioreactor that can be used to replace the above processing system. Bioreactor tank made ​​of transparent plastic tube that comes by baffles and stirrer are made ​​of stainless steel. In addition, the bioreactor is also equipped with a motor stirrer, aeration systems, and deodorizing unit. The resulting prototype has 11.078 cm high and 21.4 cm diameter, 9.2-liter operating volume, and fluid and baffle height is 24.5 cm. Bioreactor equipped with two stirrer blade that is horizontal turbine disc type at 7.13 cm of the tank bottom and paddle 4-rowing at 12.84 cm above the first blade. Bioreactor prototype has passed the leakage testand if the air flowing in at a constant velocity 0.5 m/s then the value of gasholdup (e) is 0.02. Used this prototype for further processing LCPKS cause COD value of waste fell from 4,482 mg/l to 3,096 mg/l for 30 days long processed. Normal 0 false false false IN X-NONE X-NONE

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results